Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Core Insights - Aprea Therapeutics is making significant clinical progress with its lead candidates, ATRN-119 and APR-1051, showing early evidence of anti-tumor activity and advancing towards recommended Phase 2 doses [2][4] Clinical Trials - ATRN-119 has shown tumor shrinkage in three patients (7%, 14%, and 21%) in the ongoing ABOYA-119 clinical trial, indicating its potential effectiveness against DDR-deficient cancers [2][9] - The ACESOT-1051 trial for APR-1051 is progressing, with patients currently dosed at 100 mg once daily, and preliminary efficacy data expected in the second half of 2025 [3][5] Financial Position - As of March 31, 2025, Aprea reported cash and cash equivalents of $19.3 million, down from $22.8 million at the end of 2024, which is projected to cover operating expenses into early Q2 2026 [10][15] - The company reported an operating loss of $4.1 million for Q1 2025, compared to a loss of $3.1 million in Q1 2024, with R&D expenses increasing to $2.5 million due to the initiation of new clinical trials [10][17] Business Strategy - Aprea is focused on developing therapies that exploit cancer cell vulnerabilities while minimizing damage to healthy cells, targeting cancers with specific mutations [11][9] - The company has entered into a Material Transfer Agreement with MD Anderson Cancer Center to support preclinical research on APR-1051 for treating head and neck cancers [10]